An Open-label, Fixed Sequence Study to Assess the Effect of Multiple Doses of Baxdrostat on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-childbearing Potential
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Baxdrostat (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
- Indications Hyperaldosteronism; Hypertension; Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 07 Feb 2025 Status changed from active, no longer recruiting to completed.
- 14 Jan 2025 Planned End Date changed from 17 Jan 2025 to 7 Feb 2025.
- 14 Jan 2025 Planned primary completion date changed from 17 Jan 2025 to 7 Feb 2025.